Implications of practice effects for the design of Alzheimer clinical trials [0.03%]
练习效应在阿尔茨海默病临床试验设计中的影响
Jasmin A Duehring,Diane M Jacobs,Michael L Thomas et al.
Jasmin A Duehring et al.
Introduction: Practice effects (PEs) are a well-known potential confound in natural history studies of longitudinal cognitive decline in aging and early-stage Alzheimer's disease. The implication of PEs on Alzheimer's dis...
Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY-AD and TRAILBLAZER-ALZ2 [0.03%]
Lecanemab和Donanemab治疗效果的性别差异：CLARITY-AD和TRAILBLAZER-ALZ2研究的贝叶斯重新分析
Stefan J Teipel,Yi Tang,Ara Khachaturian
Stefan J Teipel
Introduction: This study investigated evidence for or against a difference in treatment effect between women and men for lecanemab and donanemab. Methods:...
Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease [0.03%]
早期症状性阿尔茨海默病患者中多纳单抗的免疫原性
Garrett R Mullins,Paul Ardayfio,Ivelina Gueorguieva et al.
Garrett R Mullins et al.
Introduction: Donanemab is an immunoglobulin G1 antibody that targets an N-terminal truncated form of amyloid beta present in mature plaques. Treatment-emergent (TE) anti-drug antibodies (ADAs) were quantified in donanema...
Bryan Tysinger,Yifan Wei,Hanke Heun-Johnson et al.
Bryan Tysinger et al.
Introduction: An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment in...
Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers [0.03%]
关于Lecanemab的医患沟通定性研究：七个学术医学中心的医生访谈
Anna L Parks,Ayush Thacker,Daniel Dohan et al.
Anna L Parks et al.
Introduction: Anti-amyloid monoclonal antibodies (mAbs) slow cognitive decline in Alzheimer's disease but may cause amyloid-related imaging abnormalities (ARIA), which can rarely be disabling or fatal. This qualitative st...
Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP): A global effort to identify genetic factors in Alzheimer's disease [0.03%]
阿尔茨海默病多样性遗传队列的招聘和留住（READD-ADSP）：全球共同努力识别阿尔茨海默病的遗传因素
Rufus Akinyemi,Olabode Omotoso,Lwere Kamada et al.
Rufus Akinyemi et al.
Introduction: Alzheimer's disease (AD) remains a major neurocognitive disorder of global health significance. Globalizing ancestral diversity in AD genetics is essential to identify causal variants, improve diagnosis, and...
Cognitive effects of dopaminergic treatment in Alzheimer's disease: Systematic review and meta-analysis [0.03%]
多巴胺能治疗阿尔茨海默病的认知效应：系统评价和meta分析
Cristina Bonet Olivares,Michael C B David,Marta Estrada Obeso et al.
Cristina Bonet Olivares et al.
Introduction: Despite advances in disease-modifying drugs, better treatments for symptomatic Alzheimer's disease (AD) are needed, with dopaminergic neurotransmission representing a potential target. The objective of this ...
ACE trial design: Equol targeting estrogen receptor-β in vascular and cognitive aging [0.03%]
ACE试验设计：通过雌激素受体-β靶向作用来应对血管老化和认知功能衰退
Akira Sekikawa,Whitney Wharton,Cristina Murray-Krezan et al.
Akira Sekikawa et al.
Introduction: Equol, a gut microbiome-derived metabolite of soy isoflavone daidzein, functions as a selective estrogen receptor beta (ERβ) agonist. In preclinical studies, it has demonstrated vascular protective and anti...
Development and classification accuracy of an automated cognitive screening tool combining working memory and connected speech tasks for early detection of cognitive impairment in primary care [0.03%]
结合工作记忆和连贯言语任务的自动化认知筛查工具的开发及准确性研究以早期发现初级保健中的认知障碍
Robin C Hilsabeck,Jeffrey N Keller,Maya L Henry et al.
Robin C Hilsabeck et al.
Introduction: Cognitive screening to detect mild cognitive impairment (MCI) and dementia in primary care settings has proven to be a challenging task. The ideal solution would be a brief, yet sensitive, tool appropriate f...
The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients [0.03%]
血浆p-tau217/BD-tau比值可改善记忆门诊患者生物标志物的短期变异性
Frederikke Kragh Clemmensen,Fernando Gonzalez-Ortiz,Mathias Holsey Gramkow et al.
Frederikke Kragh Clemmensen et al.
Introduction: Assessment of short-term intra- and inter-individual variability for Alzheimer's disease (AD) plasma biomarkers is essential for clinically relevant interpretation of biomarker levels. We hypothesized that t...